Introduction
Hypersensitivity to heparins and heparin-like compounds is a rare condition that represents a real challenge for anaesthesiologists during cardiopulmonary bypass (CBP). We describe the case of a woman who presented hypersensitivity to heparin, fondaparinux (Arixtra) and danaparoid (Orgaran) demonstrated by allergic skin tests. She underwent mitral valve replacement surgery and hirudin was selected as anticoagulant of choice during CBP. This case report illustrates the difficulties in the management of patients known to have an allergy to heparins. We report here the use of lepirudin (Refludan) for cardiac surgery under CPB and review the alternatives for anticoagulation when heparin is contraindicated.
Case report
We evaluated a 43-year-old woman for a mitral valve replacement under CBP. Her medical history revealed multiple and severe drug allergies with an anaphylactic reaction following the first treatment with subcutaneous injection of nardroparin (Fraxodi). She had already been exposed to unfractionated heparin (UFH) (calciparin) and another low-molecular-weight heparin (LMWH) (tinzaparin, Innohep) without clinically patent hypersensitivity reaction. Her reaction to nardroparin was categorized as type I hypersensitivity (Ig-E-mediated) with angioedema, respiratory distress, urticaria and hypotension. She was treated with epinephrine, corticosteroid, dexchlorpheniramin. She also suffered from noninsulindependent diabetes, arterial hypertension, overweight, moderate congenital factor VII deficiency, acute articular rheumatism responsible for mitral insufficiency, chronic and atrial fibrillation and episodes of acute lung edema. She previously had two mitral valve repairs involving a mitral commissurotomy in 1983 followed by a valvuloplasty in 2005. Both surgeries were performed under CPB without any reaction related to the use of heparin.
The preoperative allergologic assessment confirmed that she had IgE-mediated allergic hypersensitivity to nardroparin (Fraxodi) with a cross-reaction to all commercially available LMWH, UFH in addition to danaparoid sodium (Orgaran) and fondaparinux (Arixtra). Those allergies were demonstrated by immediate skin tests (prick with pure solutions and intradermal tests positive at 1/1000 and 1/100 dilutions) and basophil activation tests. There was no evidence of cross-sensitization with lepirudin and bivalirudin. The mitral valve replacement was conducted 7 months after the anaphylactic reaction to nardroparin. Because of the allergy to heparin, we decided to use lepirudin (Refludan) during the surgery. Of note, bivalirudin (Angiox) has not been licensed for surgery under CBP in Belgium. We used a nonheparincoated CPB circuit. Anticoagulation was monitored by measuring the diluted thrombin time (dTT) named Hemoclot, the activating clotting time (ACT), the activated partial thromboplastin time (aPTT) and the international normalized ratio (INR). The ecarin clotting time (ECT) is not routinely available in our institution.
Baseline measurements before induction were as follows: dTT 31. 8 3). The first bolus of 0.4 mg/kg (35 mg) lepirudin was given at the beginning of the surgical procedure followed by a continuous infusion of 0.1 mg/kg per h (10 mg/h). A second bolus of lepirudin (15 mg) was added in the CPB priming. Anticoagulation monitoring was performed every 30 min by measurement of the dTT and the aPTT, and every 15 min by ACT. Adjustments were made to keep a therapeutic range of dTT values around 2.5 times baseline [1] . If the dTT was higher than 2.5 times baseline, infusion rate was decreased. If the dTT was under 2.5 times baseline, infusion rate was increased. Approximately 25 min after CBP beginning, the dTT values decreased and a new bolus of 10 mg was given. As illustrated in Fig. 1 , variations of the dTT were observed before modifications in ACT values. The continuous infusion was stopped after unclamping the aorta. A small clot in the CBP's oxygenator was found at the end of the procedure without any negative consequences ( Fig. 2) . Three packed red blood cell units (798 ml) were introduced in the CPB circuit during the procedure. Autologous blood transfusion from the cell saver was given at the end of the procedure with a total amount of 709 ml. No further transfusion was needed during the postoperative period. Dobutamine was required only for the first 24 postoperative hours. Anticoagulation monitoring in the immediate postoperative period was performed by aPTT. Oral anticoagulation with short-acting vitamin K antagonist (Sintrom) was initiated 4 days after the surgery and monitored by INR.
Discussion
UFH remains the standard for anticoagulation during CPB because of its rapid onset, reliable effects and reversibility with protamine sulfate [2] . Tolerance to heparin is commonly good, although few cases of immediate type I Ig-E mediated hypersensitivity reactions have been reported [3, 4] . The symptoms related with heparin hypersensitivity include urticarial rash, asthma and anaphylaxis [5] . This reaction has to be distinguished from heparin-induced thrombocytopenia type II (HIT II), which is a different immune-mediated condition occurring when IgG antibodies against platelet Cardiopulmonary bypass and allergy to heparins Balthazar et al. 901 factor 4 (PF4)-heparin complexes are present [6, 7] . Clinical entity named HIT II is identified only within a small percentage of patients, only 1% of medical patients, 3% of surgical patients and up to 5% in case of cardiac or trauma surgery [1, 6, [8] [9] [10] [11] . The frequency of HIT-IgG formation is reduced by the use of LWMH in comparison to the use of UFH [1, 10, 11] .
Alternative strategies for anticoagulation are needed during CBP when heparin cannot be used. Danaparoid (Orgaran), argatroban, tirofiban, abciximab, ancrod or prostacyline are all alternatives reported in the literature [12] . The use of hirudin has also been reported during CPB [12] [13] [14] [15] [16] [17] [18] . Hirudin refers to a group of thrombin inhibitor agents that include lepirudin and bivalirudin. We here report the case of a patient with heparin type I allergy, and hypersensitivity to fondaparinux (Arixtra) and to danaparoid (Orgaran). The use of lepirudin was guided by the patient's allergies and safety of hirudin in this particular case. Of note, bivalirudin (Angiox) has not been licensed for surgery under CBP in Belgium but could have been a well tolerated alternative.
Lepirudin is a recombinant hirudin obtained from the natural anticoagulant's leech (hirudo medicinalis). It forms irreversible 1 : 1 complexes with thrombin; it is a direct thrombin inhibitor and is able to block all of the actions of the thrombin (including transformation of the fibrinogen into fibrin and platelets' activation) [1, 11] . No antidote is currently available to counteract the anticoagulant effect of lepirudin. However, assuming normal renal function, lepirudin has a short elimination half-time [1, 11, 13, [19] [20] [21] . Renal insufficiency can lead to overdosing and bleeding because of a decrease in lepirudin elimination. The approved dose of lepirudin is a 0.4-mg/kg intravenous bolus dose followed by a continuous infusion at the rate of 0.15 mg/kg per h [11, 19, 20] . Although various target values for hirudin's blood levels have been reported during CBP, it should be kept in a range from 2.5-3.5 ml/ml to a maximum of 4-4.5 ml/ml [13, 22] . If overdosing occurs, the incidence of high postoperative blood loss becomes significant [5] . Anticoagulation monitoring can be assessed by ECT with a good correlation with lepirudin's plasmatic levels, by the aPTT and dTT measurements [10, 11, 13, 19, 22] . Therapeutic values have to be maintained between 1.5 and 2.5 times baseline [1, 19] .
The use of lepirudin instead of unfractionated heparin for systemic anticoagulation during CPB has many important implications. Reliable monitoring is essential. ACT is the usual monitoring for heparin anticoagulation under CPB because of its reproducibility, low cost and ease of use. In this case, ACT could not be used because there is no direct correlation between lepirudin plasmatic levels and ACT values. ACT variations are delayed compared with the real anticoagulation effect. The use of ECT has been described as a reliable method in the literature, but was not available in our institution at this moment [5, 22] . We used the dTT and the aPTT values during CBP. Some problems were associated with the use of those tests, among which the prolonged time delay between the blood sample and the results. Team work and collaboration between all the professionals involved at each level from operating room to laboratory can limit this time gap. It is crucial for the team to avoid underdosing because of the risk of developing clots in the CPB machine, and to avoid overdosing because of hemorr-hagic risk and absence of a specific antidote to hirudin.
Conclusion
Hypersensitivity to heparin is a rare condition found in few patients facing to CPB surgery. Systemic anticoagulation with lepirudin, although effective, is only possible with a close monitoring. The therapeutic index is very narrow and this represents a real challenge with CPB to avoid overdosing and underdosing. This case report illustrates the importance of further studies to assess the usefulness and efficiency of the measurement of the dTT in monitoring lepirudin's plasmatic level during CPB. Picture of a clot in the oxygenator after cardiopulmonary bypass.
